A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphomaReid W. Merryman, Caron A. Jacobson, Robert Redd et al.|Annals of Hematology|2023Cited by 7
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapyJennifer L. Crombie, Brian Hess, Caron A. Jacobson et al.|Haematologica|2023Cited by 6
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)Austin Kim, Mark A. Murakami, Peter A. Riedell et al.|Blood|2025Cited by 4
Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 BlockadeReid W. Merryman, Ann S. LaCasce, Justin Kline et al.|Blood|2024Cited by 3
Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular LymphomaReid W. Merryman, Caron A. Jacobson, Robert Redd et al.|Blood|2022Cited by 1